



IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

April 24, 2024

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- [IN8bio, Inc.](https://www.in8bio.com) (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

Details of the oral presentation are as follows:

Title: Healthy Donor vs Patient Manufactured Autologous Deltex DRI Product; Immunophenotyping Gene Expression

Session Type: In-Person Oral Presentation

Session Title: Novel Production Platforms

Abstract Number: 282

Location: Ballroom 2

Presentation Date/Time: Friday, May 10th at 3:45 pm – 4:00 pm ET

Abstracts are available at <https://annualmeeting.asgct.org/>. The data are embargoed until 6:00 a.m. ET on the presentation day, Wednesday May 10, 2024. A copy of the presentation will be available at <https://in8bio.com> once the presentation concludes.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.

Corporate Contact:

IN8bio, Inc.

Glenn Schulman, PharmD, MPH

203.494.7411

gdschulman@IN8bio.com

Investors

Meru Advisors

Lee M. Stern

lstern@meruadvisors.com

Media Contact

Kimberly Ha

KKH Advisors

917.291.5744

kimberly.ha@kkhadvisors.com